

# DATA ACQUISITION AND MANAGEMENT

Matt Bolt, MS

Center for Innovative Design & Analysis (CIDA)

Department of Biostatistics and Informatics

Colorado School of Public Health

[matthew.bolt@cuanschutz.edu](mailto:matthew.bolt@cuanschutz.edu)

1

# HOUSEKEEPING

## Zoom Etiquette:

- Silence personal devices.
- Stay muted when not talking.
- Set up in a quiet location.
- Remain attentive. Avoid checking email/phone/web.
- Use the Chat function to ask questions or get technical help.
- Use your full name, not an alias.

## Receiving credit for attendance:

To satisfy the [NIH Requirement for Instruction in the Responsible Conduct of Research](#), the following are required in order to receive credit for attendance:



**Attend the full 90 minutes of the training.** Attending any 8 out of the 9 RCR seminars we offer will satisfy the NIH requirement.



**Keep your video camera on throughout the session.** NIH requirements for RCR training specify face-to-face discussion.



**Participate interactively throughout the session.** Participate in discussions, respond to polls, and sign the attendance sheet (link will be distributed in the Chat).

# POLL: WHO IS THE AUDIENCE?

- 1. Select the statement that best describes you:
  - I am new to biomedical research
  - I have some previous experience with biomedical research
  - I have several years of biomedical research experience
- 2. Are you primarily working on campus or remotely/from home?
  - On campus
  - Remotely


# SOURCE OF COURSE MATERIAL

- U.S. Department of Health & Human Services (executive umbrella over NIH, CDC, FDA, etc.)
  - Office of Research Integrity (ORI)
- *ORI Introduction to the Responsible Conduct of Research*
- <https://ori.hhs.gov/education/products/RCRintro/>

# THEMES OF PRESENTATION

- **Replicability** is obtaining consistent results across studies aimed at answering the same scientific question, each of which has obtained its own data.
- **Reproducibility** is obtaining consistent results using the same input data; computational steps, methods, and code; and conditions of analysis.
- **Generalizability** is the extent that results of a study apply in other contexts or populations that differ from the original one.

# THREATS TO REPLICABLE SCIENCE




# THREATS TO REPLICABLE/REPRODUCIBLE SCIENCE

- Sources of non-replicability/non-reproducibility:
  - Inadequate recordkeeping
  - Selective reporting and/or analysis
  - Cultural barriers
  - Obsolescence of digital artifacts
  - Lack of expertise to reproduce other's research

*Reproducibility and Replicability in Science*. National Academies, 2019.

- “...asking questions at the design stage can save headaches at the analysis stage: careful data collection can greatly simplify analysis and make it more rigorous”

Kass, R. E. et al. Ten simple rules for effective statistical practice. PLoS Comput. Biol. 12, e1004961 (2016)



**Poll:** How reproducible has research been?



# A FEW EXAMPLES FROM THE LITERATURE

- Data access for reproducing results [is] available in 20%-25% of a sample of studies in biology.

Prinz et al. (2011)

- From NIH-funded studies, only 12% [of studies] provided datasets in recognized repositories.

Read et al. (2015)

- Out of 268 manuscripts on biomedical research, none provided access to all raw data used in the study.


Iqbal et al. (2016)

- Evaluation of the *PLOS ONE* open data policy revealed that 20% of published studies still had restrictions on data access.

Byrne (2017)

# OBJECTIVES OF PRESENTATION

- Specimens (*Replicability*)
  - Common Errors
  - Guidance on best practices
- Data Collection, Storage, and Ownership (*Replicability*)
  - Learn general guidelines for unbiased data **collection**
    - *Best practices – how to find help!*
  - Know the 3 top things to consider when **storing** data
  - Explain who **owns** research data and with who and how it should be **shared**
- Statistical work and analysis (*reproducibility*)
  - Guiding principals for analysis
- Pitfalls



# SPECIMENS

Collection Considerations  
for Replicable Results

Slides provided by Nassia  
Duncan, Lab Manager

# CATASTROPHIC SCENARIOS: PART 1

- All samples are labeled with paper labels that are taped over with scotch tape for security before freezing. Adhesive fails in -80 freezer and tape peels off, taking all the ink with it. Samples are now unidentifiable. No data can be collected.
- Labeled samples are placed in an unlabeled box and put in the freezer. Two weeks later the lab attempts to locate samples among 300 other boxes. Samples are never found. No data is collected
- Each sample is labeled with permanent marker, but the handwriting is illegible. Lab makes best guess at reading the chicken scratch. Samples are mis-labeled and results are not replicable.
- Liquid samples are thrown in the freezer and land on their sides. Freezing expands the sample and pushes the lid off, exposing the sample to air and contamination. When the sample is thawed it leaks. Results are not replicable.

# CATASTROPHIC SCENARIOS: PART 2

- Procedure says to freeze sample immediately, but sample isn't frozen for three hours because of incident in OR. Incident is not recorded and testing proceeds as normal. Why are these results not replicable?
- Samples are pipetted from primary container into secondary storage container. PRA doesn't use a new pipette for each sample because it's not in the procedure. Why are these results not replicable?
- Saliva and urine samples are collected, placed in a bag, and shipped by air to a lab. The pressure changes force saliva and urine out of their containers, compromising the lids. Why are these results not replicable?

# PROTECTING YOUR DATA STARTS AT SAMPLE COLLECTION

- Go through every step of the collection, shipping, and testing process. What is that sample going to go through?
  - What containers will be used? How are they sealed?
  - Label Everything Always!
    - Label primary and secondary containers. Keep a log of what you've collected and **where it is**. Who has it and when?
    - Keep labels consistent. The first collection of an experiment cannot change from "Baseline collection" to "Collection 0" six months into sampling.
    - Legibility. Can everyone at every stage of testing read that label?
    - Will labeling survive the freezer and multiple freeze/thaw cycles? Many adhesives are non-functional if exposed to extreme cold or any moisture.
- The clearer and more detailed your collection procedure, the better off you are.

# QUESTIONS TO CONSIDER

- Is container watertight for biological samples? (And will **remain** so?)
- Will samples be shipped upright?
- What is the potential for leakage/breakage?
- Are different sample types packaged separately in case of leaks?
- Will samples be shipped by air? (pressure and temperature changes)
- Is shipping time sensitive? (dry ice, frozen samples, temperature sensitive samples)
- Have you followed federal guidelines for shipping biological or hazardous substances?





## Data Collection

16



# DATA COLLECTION

1. Are there guidelines/regulations you need to follow?
  - HIPAA, hazardous materials, copyrights, consent forms
2. Use appropriate methods!

“Failure to find the effect could be due to either your experimental design or the lack of an effect, but you will not know which is true.”
3. Define data items and guidelines for recording them
4. Determine the physical process of recording the data
  - Notebook (hard copy)
  - Computer file or electronic notebook (electronic copy)

Taken from *ORI Introduction to RCR*  
(<http://ori.hhs.gov/education/products/RCRintro/>)

# DO NOT RECREATE THE WHEEL

- When starting a new project use existing resources or a colleague!
  - What resources are publicly available or provided by your institution?
  - What processes do we know that *don't* work?
    - Search terms: Data collection, best practices, Data management, Guidelines, lessons learned
    - Experimental Design expertise
- Organization (next several slides)
  - Folder Organization
  - ReadME
  - Data Dictionary
  - Data Collection SOP
  - Defined Roles and Responsibilities
  - Electronic Laboratory Notebooks
  - Data Collection Software (e.g., REDCap)
- Make sure your data is usable for analysis
  - (European Spreadsheet Risks Interest Group)

# FOLDER ORGANIZATION

## Folders

### 1. Data

- a. Raw Data
- b. Data Dictionary
- c. Analytic files

### 2. Program

- a. Code used to generate raw data files (if applicable)
- b. Secondary files (if applicable)
- c. Code used to create analytic files
- d. Analysis Code/ Script
- e. Program Log from Statistical Program|

### 3. Results

- a. Tables, charts, graphs, etc.
- b. Drafts by Date
- c. Preliminary Findings
- d. Final Report

### 4. Background

- a. Lit review
- b. Documentation from partner
- c. Relevant background

# README

## README

\*\*\*\*\*  
\*\*\*\*\*  
Project Name:

Executive Sponsor:

Champion:

Comirb#

Analyst:

\*\*\*\*\*  
\*\*\*\*\*  
**\*\*Background\*\***\*\*\*\*\*  
\*\*\*\*\*

*List all files and source of information, i.e. who sent it to you if applicable*

\*\*\*\*\*  
**\*\*Data\*\***\*\*\*\*\*  
\*\*\*\*\*

*List each dataset in file, these should be analyzable datasets with a brief description of what they are for.*

**\*\*Data/RawData\_DONOTDELETE\*\***\*\*\*\*\*

*All raw data provided on project is stored in here, these are not to be overwritten.*


\*\*\*\*\*  
**\*\*NavLabDocumentation\*\***\*\*\*\*\*  
\*\*\*\*\*

*Protocol, intake form, SOW, COMIRB, All analytical plans are to be stored in this folder and each file listed.*

\*\*\*\*\*  
**\*\*Program\*\***\*\*\*\*\*  
\*\*\*\*\*

*Each program to analyze the data should be listed, the purpose of the program and if multiple programs to get to a result are needed then document the order they need to be run in.*

# SDM4Afib: Enrollment Flow Diagram



## Randomization/Data Entry Instructions

REDCap will be used for data entry and randomization. Study coordinators at each site will randomize the patients prior to the clinical encounter with the enrolled clinician.

All study staff questions should be directed to xx and xx

All access for data entry or issues with software for data entry should be directed to the statistical team xx and xx

### Clinician enrollment:

After a clinician has been consented, the study coordinator will assign the clinician a study id. You will have the clinician complete the baseline enrollment survey to obtain their demographics. This data is collected only at time of enrollment. If the clinician being consented does not have time to complete survey prior to participating in the trial with an enrolled patient, then the survey can be completed after the encounter. The data is to be entered into the redcap database called “SDM for AFib: Clinician Baseline Survey – AL & MS Sites” within 7 days of first enrolled patient otherwise considered overdue. A scanned copy of the consent along with a scanned copy of the completed survey will be uploaded to the database as well (for Park Nicollet, HCMC, U of Mississippi, and U of Alabama only). Once all clinicians have been enrolled for your site you will not need to use this again.

- Format for clinician ID’s:
  - example “AF\*Site\*Clinician\*001”;
  - where site is either ‘M’=Mayo Clinic Rochester,
    - ‘E’=‘Mayo Clinic Emergency Department’ or
    - ‘P’=Park Nicollet or
    - ‘H’=HCMC or ‘
    - ‘J’=University of Mississippi or
    - ‘A’=University of Alabama
  - and the number starts at 001 and increases incrementally as you enroll clinicians.
  - Example: AFMC001, first enrolled clinician at Mayo
  - The numbers do not need to be incremental.
  - If you made an error in entry of the ID into REDCap, contact the statistical team for them to correct.

| Field Name                           | Comment   |
|--------------------------------------|---|
| Enrolled Patient ID                  | This is the ID generated by the study coordinator.  |
| Staff Initials                       | Enter the initials of the staff member at the site that is approaching the patient for enrollment: First, Middle, Last<br>If the middle initial is not known, enter a dash (-).   |
| Clinic Location                      | Choose enrolling site   |
| Medication Cohort                    | Start – Patients that have not taken an anticoagulant within 6 months of enrollment.<br>Review – Has a prescription for an anticoagulant and taken medication within 6 months.  |
| CHADS-VASc Score                     | Choose: For men with a score of 1 or women with a score of 2<br>Or<br>For men with a score greater than 1 or greater than 2 for women.  |
| Arm Assignment^                      | This is the randomization tool, confirm that the medication cohort and CHADS-VASc score has been entered correctly prior to clicking the button for randomization. The tool will ask you to confirm the data prior to randomization and will provide an error if the required information is not obtained. After you have confirmed the data is accurate you will click the ‘randomize’ button. If the data is inaccurate you make your correction within that screen and then select ‘randomize’. The changes to the medication cohort and CHADS-VASc will be saved. The arm assignment that is provided is final. |
| Signed consent form                  | Upload a .pdf or .doc copy of the patients signed consent form.   |
| Patient eligibility CRF              | Provided a .pdf or .doc of the completed eligibility CRF.   |
| Patient excluded after randomization | If a patient is found to be ineligible after consent then this field will be checked and the reason for ineligibility will need to be provided. If the patient consents and then withdraws* then check this field and provide the reason and note within the text field that they are a withdraw.   |



# **ELECTRONIC LABORATORY NOTEBOOKS (ELN) & LABARCHIVES**

- Electronic data management platforms that serve as repositories and organizational tools for research data
- Easier to follow data management plan
- Control access, organization, sharing, and archiving
- Secure
- LabArchives is provided to Anschutz faculty and staff for free, might require fee for students
  - Secure and cloud-based
  - Discipline agnostic
  - Shared notebooks
  - Enables compliance with data management requirements

# LABARCHIVES RESOURCES

- Website: <https://research.cuanschutz.edu/university-research/labarchives>
- Support: [support@labarchives.com](mailto:support@labarchives.com)
- Tutorials, articles, etc:  
<https://www.labarchives.com/labarchives-knowledge-base/>
- Lunch and learn video:  
<https://www.youtube.com/watch?v=eDYm-nQTAX4>



# DATA COLLECTION CASE STUDY


## FROM *RESPONSIBLE CONDUCT OF RESEARCH*

- Dr. Z is mentoring a medical student over the summer in his research lab
- Student's project
  - Cancer cell line that requires 3 weeks to grow to test for a specific antibody
  - Student has already written a short paper on his work
- Dr. Z's dilemma:
  - Raw data on pieces of yellow pads without clear identification of the experiment from which the data came
  - Some experiments were repeated several times without explanation
  - Doesn't want to discourage student from pursuing a career in research
- What is the primary responsibility of the mentor?
- Should the mentor write a short paper and send it for publication?
- Should the student write a short paper and send it for publication?
- If you were the mentor, what would you do?

## Welcome to REDCap!

REDCap is a secure web platform for building and managing online databases and surveys. REDCap's streamlined process for rapidly creating and designing projects offers a vast array of tools that can be tailored to virtually any data collection strategy.

REDCap provides automated export procedures for seamless data downloads to Excel and common statistical packages (SPSS, SAS, Stata, R), as well as a built-in project calendar, a scheduling module, ad hoc reporting tools, and advanced features, such as branching logic, file uploading, and calculated fields.

Learn more about REDCap by watching a  [brief summary video \(4 min\)](#). If you would like to view other quick video tutorials of REDCap in action and an overview of its features, please see the [Training Resources](#) page.

Please note that any publication that results from a project utilizing REDCap should cite grant support (**NIH/NCATS Colorado CTSA Grant Number UL1 TR002535**).

**NOTICE:** If you are collecting data for the purposes of human subjects research, review and approval of the project is required by your Institutional Review Board.

If you require assistance or have any questions about REDCap, please contact [REDCap Admin](#).

For REDCAP TIPS, [click here](#) to visit the UC Denver REDCap Information website.

## REDCap Features

### **Build online surveys and databases quickly and securely in your browser**

- Create and design your project using a secure login from any device. No extra software required. Access from anywhere, at any time.

**Fast and flexible** - Go from project creation to starting data collection in less than one day. Customizations and changes are possible any time, even after data collection has begun.

**Advanced instrument design features** - Auto-validation, calculated fields, file uploading, branching/skip logic, and survey stop actions.

**e-Consent** - Perform informed consent electronically for participants via survey.

**Diverse and flexible survey distribution options** - Use a list of email addresses or phone numbers for your survey respondents and automatically contact them with personalized messages, and track who has responded. Or create a simple link for an anonymous survey for mass email mailings, to post on a website, or print on a flyer.

**REDCap Mobile App** - Collect data offline using an app on a mobile device when there is no WiFi or cellular connection, and then later sync data back to the server.




**Data quality** - Use field validation, branching/skip logic, and Missing Data Codes to improve and protect data quality during data entry. Open data queries to automatically identify and resolve discrepancies and other issues real-time.

**Custom reporting** - Create custom searches for generating reports to view aggregate data. Identify trends with built-in basic statistics and charts.

**Export data to common analysis packages** - Export your data as a PDF or as CSV data for easy analysis in SAS, Stata, R, SPSS, or Microsoft Excel.

**Secure file storage and sharing** - Upload and share any type of file with anyone in the world through the File Repository feature or Send-It tool. Also works with exports and other built-in file uploading features.

# REDCAP AND TIDY DATA



|    | A | B | C                                      | D              | E | F                   | G                   |
|----|---|---|--|----------------|---|---------------------|---------------------|
| 1  |   |   |  |                |   |                     |                     |
| 2  |   |   |  |                |   |                     |                     |
| 3  |   |   | <b>Gross domestic product 2021</b>     |                |   |                     |                     |
| 4  |   |   |  |                |   |                     |                     |
| 5  |   |   |  |                |   |                     | <i>(millions of</i> |
| 6  |   |   |  | <i>Ranking</i> |   | <i>Economy</i>      | <i>US dollars)</i>  |
| 7  |   |   |  |                |   |                     |                     |
| 8  |   |   | USA                                    | 1              |   | United States       | 22,996,100          |
| 9  |   |   | CHN                                    | 2              |   | China               | 17,734,063          |
| 10 |   |   | JPN                                    | 3              |   | Japan               | 4,937,422           |
| 11 |   |   | DEU                                    | 4              |   | Germany             | 4,223,116           |
| 12 |   |   | GBR                                    | 5              |   | United Kingdom      | 3,186,860           |
| 13 |   |   | IND                                    | 6              |   | India               | 3,173,398           |
| 14 |   |   | FRA                                    | 7              |   | France              | 2,937,473           |
| 15 |   |   | ITA                                    | 8              |   | Italy               | 2,099,880           |
| 16 |   |   | CAN                                    | 9              |   | Canada              | 1,990,762           |
| 17 |   |   | KOR                                    | 10             |   | Korea, Rep.         | 1,798,534           |
| 18 |   |   | RUS                                    | 11             |   | Russian Federation  | 1,775,800           |
| 19 |   |   | BRA                                    | 12             |   | Brazil              | 1,608,981           |
| 20 |   |   | AUS                                    | 13             |   | Australia           | 1,542,660           |
| 21 |   |   | ESP                                    | 14             |   | Spain               | 1,425,277           |
| 22 |   |   | MEX                                    | 15             |   | Mexico              | 1,293,038           |
| 23 |   |   |  |                |   |                     |                     |
| 24 |   |   |  |                |   | Mean:               | 4,848,224           |
| 25 |   |   |  |                |   | Standard deviation: | 6465509.324         |
| 26 |   |   |  |                |   |                     |                     |
| 27 |   |   | *Note: only the top 15 countries shown |                |   |                     |                     |
| 28 |   |   | *Units for money is US dollars         |                |   |                     |                     |
| 29 |   |   |  |                |   |                     |                     |
| 30 |   |   | DON'T FORGET TO RUN THE T-TEST!!       |                |   |                     |                     |

|    | A                           | B   | C                                      | D       | E                  | F           | G |
|----|-----------------------------|-----|--|---------|--------------------|-------------|---|
| 1  |                             |     |  |         |                    |             |   |
| 2  |                             |     |  |         |                    |             |   |
| 3  | Gross domestic product 2021 |     |  |         |                    |             |   |
| 4  |                             |     |  |         |                    |             |   |
| 5  | (millions of                |     |  |         |                    |             |   |
| 6  | Ranking                     |     |  | Economy |                    | US dollars) |   |
| 7  |                             |     |  |         |                    |             |   |
| 8  |                             | USA | 1                                      |         | United States      | 22,996,100  |   |
| 9  |                             | CHN | 2                                      |         | China              | 17,734,063  |   |
| 10 |                             | JPN | 3                                      |         | Japan              | 4,937,422   |   |
| 11 |                             | DEU | 4                                      |         | Germany            | 4,223,116   |   |
| 12 |                             | GBR | 5                                      |         | United Kingdom     | 3,186,860   |   |
| 13 |                             | IND | 6                                      |         | India              | 3,173,398   |   |
| 14 |                             | FRA | 7                                      |         | France             | 2,937,473   |   |
| 15 |                             | ITA | 8                                      |         | Italy              | 2,099,880   |   |
| 16 |                             | CAN | 9                                      |         | Canada             | 1,990,762   |   |
| 17 |                             | KOR | 10                                     |         | Korea, Rep.        | 1,798,534   |   |
| 18 |                             | RUS | 11                                     |         | Russian Federation | 1,775,800   |   |
| 19 |                             | BRA | 12                                     |         | Brazil             | 1,608,981   |   |
| 20 |                             | AUS | 13                                     |         | Australia          | 1,542,660   |   |
| 21 |                             | ESP | 14                                     |         | Spain              | 1,425,277   |   |
| 22 |                             | MEX | 15                                     |         | Mexico             | 1,293,038   |   |
| 23 |                             |     |  |         |                    |             |   |
| 24 | Mean:                       |     |  |         |                    | 4,848,224   |   |
| 25 | Standard deviation:         |     |  |         |                    | 6465509.324 |   |
| 26 |                             |     |  |         |                    |             |   |
| 27 |                             |     | *Note: only the top 15 countries shown |         |                    |             |   |
| 28 |                             |     | *Units for money is US dollars         |         |                    |             |   |
| 29 |                             |     |  |         |                    |             |   |
| 30 |                             |     | DON'T FORGET TO RUN THE T-TEST!!       |         |                    |             |   |

|    | A       | B       | C                  | D          |
|----|---------|---------|--------------------|------------|
| 1  | Country | Ranking | <i>Economy</i>     | USD        |
| 2  | USA     | 1       | United States      | 22,996,100 |
| 3  | CHN     | 2       | China              | 17,734,063 |
| 4  | JPN     | 3       | Japan              | 4,937,422  |
| 5  | DEU     | 4       | Germany            | 4,223,116  |
| 6  | GBR     | 5       | United Kingdom     | 3,186,860  |
| 7  | IND     | 6       | India              | 3,173,398  |
| 8  | FRA     | 7       | France             | 2,937,473  |
| 9  | ITA     | 8       | Italy              | 2,099,880  |
| 10 | CAN     | 9       | Canada             | 1,990,762  |
| 11 | KOR     | 10      | Korea, Rep.        | 1,798,534  |
| 12 | RUS     | 11      | Russian Federation | 1,775,800  |
| 13 | BRA     | 12      | Brazil             | 1,608,981  |
| 14 | AUS     | 13      | Australia          | 1,542,660  |
| 15 | ESP     | 14      | Spain              | 1,425,277  |
| 16 | MEX     | 15      | Mexico             | 1,293,038  |

| Name | Race               | Age  | Employment | Cancer Date | Cancer sta           | Script not                          | T/A use                      | Substance | 3 mo narc | 6 mo narc | Date of Dea  |
|------|--------------------|------|------------|-------------|----------------------|-------------------------------------|------------------------------|-----------|-----------|-----------|--------------|
| PA   | non-hispanic       | 59 Y |            | Apr-08      | 1b1 Grade II endocer | Y-smoker until 1992 (20 pack yr hx) |                              | N         | unknown   | unknown   | 1/29/2014    |
| MA   | white or caucasian | 56   | No         | May-00      | IIIB SCC             | On Norco                            | former smoker                | N         | unknown   | unknown   | 2/6/2014     |
| JA   | hispanic           | 53 Y |            | Sep-10      | 1B2 grade            | n/a                                 | N                            | N         | N         | N         | NA           |
| CA   | non-hispanic       | 47 Y |            | Sep-09      | IB2 cervic           | n/a                                 | Y- 2.5 pack years            | N         | unknown   | unknown   | n/a          |
| CA   | hispanic           | 52   | unknown    | Jul-13      | stage IVA            | percocet                            | Y- 16 pack year              | N         | Y         | Y         | unsure but c |
| PA   | non-hispanic       | 76   | retired    | May-10      | IIIC                 | n/a                                 | T-40 pack year former smoker | N         | N         | N         | n/a          |
| RA   | hispanic           | 40   | unknown    | 2/5/2015    | IIIB                 | n/a                                 | Y- hx alcohol abuse          | Y hx coca | Y         | Y         | unsure but c |
| AE   |                    | 69   |            |             | IBI                  |                                     |                              |           |           |           |              |
| LA   |                    |      |            | Jun-00      | microinvasive        |                                     |                              |           |           |           |              |
| AB   | non-hispanic       | 44   | unknown    | 6/26/2015   | IBI                  |                                     | Y- 15 PY                     | N         | Y         | N         | n/a          |
| AB   | hispanic           | 44   | unknown    | Mar-09      | IVB                  | unknown                             | N                            | N         | unknown   | unknown   | n/a          |
| LB   | non-hispanic       | 66   | unknown    | May-05      | IVB                  | n/a                                 | N                            | N         | unk       | unknown   | n/a          |
| BA   | non-hispanic       | 33   | student    | 12/7/2015   | IIB                  | chronic pa                          | Former smoker                | Y         | Y         | ***       | n/a          |
| AB   |                    |      |            |             |                      |                                     |                              |           |           |           |              |
| GB   | non-hispanic       | 84   | N          | Jan-13      | IIB                  |                                     | N                            | N         | N         | N         | n/a          |
| SB   | non-hispanic       | 48   | Y teacher  | 5/4/2012    | IIB                  |                                     | N                            | N         | Y         | N         | n/a          |



# DATA STORAGE

# DATA STORAGE

“Over time, data, as the currency of research, become an investment in research. If the data are not properly protected, the investment, whether public or private, could become worthless”

– ORI Introduction to RCR

**Poll:** How long do you have to store study material (Period of retention) per AMC guidelines?

University of Colorado Denver | Anschutz Medical Campus  
Record Retention Matrix  
8/22/2022

| DocumentType  | Repository   | Retention Period   | Related Authority                                     |
|---|--|--|---|
| <b>Grant and Research Records</b>   |  |  |   |
| Clinical Research Records<br>Protocols<br>Patient Records<br>Regulatory Records<br>Associated Contracts<br>Accounting Records   | Department   | 2 years post marketing approval or IND withdrawal  |   |
| Grant Project Research Records<br>Activity Reports<br>Conflict of Interest Disclosures<br>Research Data<br>Summary Reports<br>Working Papers<br>Related Documentation | Office of Grants and Contracts, Academic Departments, Regulatory Compliance or other repository as designated. | 9 years after expiration of grant funding period or termination of contract and until no longer needed for reference.                    | State Archives Records Management Manual - Schedule 8 |
| Grants, Contracts, and Awarded Proposal Records   | Department   | 6 years after the project becomes inactive and until no longer needed for reference or as otherwise provided for by the award documents. | State Archives Records Management Manual - Schedule 8 |

**Poll:** Where can study data be safely stored?

# CONSIDERATIONS WHEN STORING DATA/RESEARCH RECORDS



Taken from *ORI Introduction to RCR*

(<http://ori.hhs.gov/education/products/RCRintro/>)

- Catastrophe
  - Lab notebooks are in a “safe” place
  - Electronic data are backed up and stored in a separate location
  - Samples are stored properly to avoid contamination (*mice*)
- Confidentiality
  - Information on human subject – see HIPAA guidelines
  - Information on intellectual property
- Period of retention
  - NIH generally requires 3 years after project end
  - Other agencies may require up to 7 years after project end
  - University of Colorado AMC requires 9 years after grant end
  - Other unforeseen uses...

# POSSIBLE ELECTRONIC DATA STORAGE LOCATIONS

- Email safe guards:  
<https://www.ucdenver.edu/offices/office-of-information-technology/secure-campus/encryption>
- OneDrive: <https://www.cuanschutz.edu/offices/office-of-information-technology/tools-services/for-faculty/detail-page/microsoft-onedrive-for-business>

The screenshot shows the University of Colorado Denver | Anschutz Medical Campus website. The header includes navigation links: Webmail, UCD Access, Canvas, Quick Links, and a search icon. A sidebar on the left lists various services: Office 365, OneDrive, Qualtrics, Skype for Business, University Credentials, VPN and Remote Access, and Zoom. The main content area features a 'Stay Secure' section with text about HIPAA compliance and a link to learn how to stay secure while sharing files with OneDrive. Below this is a video player with the title 'Get started with OneDrive at work' and a play button icon. The video thumbnail shows a laptop screen displaying the OneDrive interface.

University of Colorado Denver | Anschutz Medical Campus

Webmail UCD Access Canvas Quick Links

Office 365

OneDrive »

Qualtrics

Skype for Business

University Credentials

VPN and Remote Access

Zoom

**Stay Secure**

OneDrive is configured for [HIPAA compliance](#), so files are all private by default. However, sharing for viewing and editing is easy to do. [Learn how to stay secure while sharing files with OneDrive.](#)

**Get Help**

- [Share OneDrive files with external users](#)
- [Share OneDrive files and folders](#)
- [Mac FAQs](#)
- [Delete or restore files and folders](#)

Get started with OneDrive at work

# CONSIDERATIONS FOR IMAGING DATA

- Human imaging data should be treated as identifiable data
- This should be stored on the Isilon server
- You may need to help pay for storage space depending on the file size
- Computing should be done on a server behind the university firewall
- Non-human subject data does not require HIPAA-compliant storage but will require sufficient storage space

# DATA OWNERSHIP / SHARING

# OWNERSHIP/DATA SHARING

Who owns the data?

- Researcher
- Funding Agency
  - Grant
- Data Repository
  - Subject
  - Community

“for the most part, NIH makes awards to institutions and not individuals”

– *NIH Data Sharing Policy and Implementation Guidance*

- Research Institutions




Illustration by David Zinn



# NIH DATA MANAGEMENT AND SHARING POLICY (DMSP) – STARTED JANUARY 25, 2023

- Plan and budget for managing and sharing data
  - Identify appropriate repository
  - Develop a Data Management and Sharing (DMS) plan
  - Estimate funding needed to execute this plan
- Submit a DMS plan when applying for NIH funding
  - Will be reviewed by NIH program staff, not peer review
  - Must be approved prior to award
- Comply with plan during study
  - Provide updates on DMS activities in annual progress reports
  - Work with program officer to review and approve modifications

# DMSP RESOURCES AT AMC

- The Research Informatics Office (RIO)
  - Webinars and Town Halls
  - Definitions of required elements
  - Templates
  - Budgeting and compliance
- NIH webinars
- Budgeting – NIH FAQ
  - You MUST budget for this: can't cover this with other FTE

43

ON TEENAGERS, ADULT:

Statistics show that teen pregnancy drops off significantly after age 25.

*Mary Anne Tebedo, Republican state senator from Colorado Springs  
(contributed by Harry F. Pancer)*

MONDAY

DECEMBER 1999

## Statistical Analysis

*(replicability -> reproducibility)*

# TIPS FOR REPRODUCIBLE STATISTICAL ANALYSES

1. ALWAYS keep a version of the “most raw” data
  - Record when and where it was created, so you can easily tell if it has been changed since creation
2. Use a scripting language
  - Programs like R and SAS allow you to follow your steps exactly if you (or someone else) had to redo your analysis
  - Easily execute and document QC steps
  - Avoid copy/paste errors
  - **NO EXCEL! POINT-AND-CLICK = NOT GREAT!**
3. Add comments/notes directly to program
  - Why are you doing this step?
  - What is the goal of this step?
4. Use Version Control (i.e. GitHub or GitLab)
5. Export precise tables/figures from program
  - Avoid transposition errors
  - Save time/energy when changes are requested

```

raw_df <- here("DataRaw", "AMH Combined Data Sets_2.5.24.xlsx") %>% read_excel()

df <- raw_df

df$site <- with(df, ifelse(`Site (0= Iowa; 1= CU-AM` == 1, "CO", "IA"))
df$BMI <- with(df, as.numeric(BMI))

df$AMH_ln <- log(df$AMH)

df$AnyPreeclampsia_simple <- with(df, ifelse(AnyPreeclampsia %in% c("No", "No prior delivery"), "No", AnyPreeclampsia))

df$Parity <- as.numeric(df$Parity)
df$NumberMiscarriages <- as.numeric(df$NumberMiscarriages)
df$MenarcheAge <- as.numeric(df$MenarcheAge)
df$Gravidity <- as.numeric(df$Gravidity)

# I make this big variable in order to clearly figure out who has and hasn't given birth. The reason for such detail is 1) because I like accuracy and 2) because then I can make sure I can distinguish those who did and did not give birth when I calculate complications.
df$HasDelivered_temp <- with(df, ifelse(! (DayssinceLastDelivery %in% c("No prior delivery", "Unknown")), "Delivered",
  ifelse(Parity > 0, "Delivered",
    ifelse(PriorIVFPreg %in% "Yes", "Delivered",
      ifelse(AnyPreterm %in% c("No", "Yes") |
        AnyPreeclampsia %in% c("No", "Yes") |
        AnyFGR %in% c("No", "Yes") , "Delivered",
        ifelse(AnyPreterm == "No prior delivery" |
          AnyPreeclampsia == "No prior delivery" |
          AnyFGR == "No prior delivery", "No prior delivery",
"unknown"))))))))
df$HasDelivered <- with(df, ifelse(is.na(HasDelivered_temp), "Unknown", HasDelivered_temp))

# Make sure the complications variable has a space for "no prior delivery" (which is why the detailed variable above was so helpful).
df$complication <- with(df, ifelse(HasDelivered == "Unknown", "Unknown",
  ifelse(HasDelivered == "No prior delivery", "No prior delivery",
    ifelse(AnyPreterm == "No" & AnyPreeclampsia == "No" & AnyFGR == "No", "No",
      ifelse(AnyPreterm == "Yes" | AnyPreeclampsia == "Yes" | AnyFGR == "Yes", "Yes",
"unknown"))))))

df <- df %>%
  rename(smoking = TobaccoUse,
    hyper_meds = TakingAntihypertensives)

df$DayssinceLastDelivery <- as.numeric(df$DayssinceLastDelivery)

```


# OUTLIERS

46


Sign the **Attendance** Sheet now by clicking the link in the Chat.

# OUTLIERS

With Outlier



Without Outlier



# OUTLIER MITIGATION

## 1. Identify

- 2 or 3 standard deviations
- Unrealistic values
- Inconsistent

## 2. Investigate

- Was there a technical issue? typo? etc?
- Is it even a possible true value?

## 3. Remediate with DOCUMENTATION

- Make a rule and write it down

## 4. Sensitivity analysis

- What would have happened if you hadn't eliminated values? Is your result robust?



# P-VALUES


50

# DO YOU KNOW WHAT A P-VALUE IS?

**Poll:** What is the definition of a p-value?

# WHAT IS A P-VALUE?

- P-values tell us how likely you are to get the same result (or one more extreme) assuming that your null hypothesis is true
- They are commonly misinterpreted
- Null hypothesis: the hypothesis you are trying to *disprove*
  - “Adult males and females have the same mean height”
  - “There is no correlation between smoking status and development of lung cancer.”



A **p-value** (shaded green area) is the probability of an observed (or more extreme) result assuming that the null hypothesis is true.

- <https://www.simplypsychology.org/p-value.html>

# MORE INTUITION FOR P-VALUES

- <https://www.rossmanchance.com/ISlapplets.html>

# IS THERE VALUE IN P-VALUES?

- In most cases you cannot directly compare p-values (must be from exact same sample and same outcome)
- Statistical significance does not indicate clinical significance

# WHAT IS P-HACKING?

- Stop collecting data once  $p < 0.05$
- Report only measures or outcomes with  $p < 0.05$
- Use covariates to get  $p < 0.05$
- Exclude participants to get  $p < 0.05$
- Transform data to get  $p < 0.05$

| <u>P-VALUE</u> | <u>INTERPRETATION</u>                                  |
|----------------|--|
| 0.001          | HIGHLY SIGNIFICANT                                     |
| 0.01           |  |
| 0.02           |  |
| 0.03           |  |
| 0.04           | SIGNIFICANT  |
| 0.049          |  |
| 0.050          | OH CRAP. REDO CALCULATIONS.                            |
| 0.051          | ON THE EDGE OF SIGNIFICANCE                            |
| 0.06           |  |
| 0.07           | HIGHLY SUGGESTIVE, SIGNIFICANT AT THE $P < 0.10$ LEVEL |
| 0.08           |  |
| 0.09           |  |
| 0.099          | HEY, LOOK AT THIS INTERESTING SUBGROUP ANALYSIS        |
| $\geq 0.1$     |  |

Please, do not do this



# WHAT HAPPENS WHEN YOU P-HACK


The  $p < 0.05$  threshold assumes a 5% type I error rate, but...



As the number of statistical comparisons increases



The type I error rate increases





# HOW TO AVOID P-HACKING

- Determine a primary analysis a priori and stick to that analysis
- Adjust for multiple comparisons
- Interpret your findings in an exploratory context instead of a confirmatory context
- Compare effect sizes, which are usually more clinically relevant when discussing your results

# THE DARK SIDE OF P-HACKING

11/5/2018


A top Cornell food researcher has had 15 studies retracted. That's a lot. - Vox

**Vox**

## **A top Cornell food researcher has had 15 studies retracted. That's a lot.**

Brian Wansink is a cautionary tale in bad incentives in science.

By Brian Resnick and Julia Belluz | Updated Oct 24, 2018, 2:25pm EDT



Brian Wansink just had six papers retracted from top journals. | Jason Koski

Work cited more than 20,000 times.

‘the misreporting of research data, problematic statistical techniques, failure to properly document and preserve research results and inappropriate authorship.’

# HELPFUL RESOURCES


- Biostats4U – Statistical resources for non-statisticians
  - <https://biostats4you.umn.edu/>
- UCLA IDRE - Statistical methods across multiple programming languages with real world problems with explanations of code and interpretation of output
  - <https://stats.idre.ucla.edu/other/mult-pkg/whatstat/>
- Nature – Points of Significance Articles
  - <https://www.nature.com/collections/qghhqm/pointsofsignificance>

# KEY ITEMS TO REMEMBER

- Do not do anything to your data that you are not willing to explain in a publication!
- Document everything
- Store your data securely
- Plan analyses before you collect data
- Know your assumptions with your data
- Do not work as an island – when in doubt, ask!

# NEED MORE STATS HELP?

- <https://coloradosph.cuanschutz.edu/research-and-practice/centers-programs/cida>



colorado school of public health

## Center for Innovative Design & Analysis

Connect With Us ▼ Consulting Clinics Learning ▼ Research About Us ▼ News & Events ▼

- One Time Projects
- Build a Partnership
- Grant Development
- One Hour Consultation

Building teams through innovation and science

# ACKNOWLEDGEMENTS / REFERENCES

- Dr. Laura Saba
  - Dr. Paula Hoffman
  - ORC and CCTSI
  - Dr. Camille Hochheimer
- Nassia Dunn  
Dr. Brandie Wagner  
Megan Branda

<https://research.cuanschutz.edu/regulatory-compliance>

## References

*Reproducibility and Replicability in Science.*

(<https://nap.nationalacademies.org/catalog/25303/reproducibility-and-replicability-in-science>)  
National Academies, 2019.

*Responsible Conduct of Research* by Adil E Shamoo and David B. Resnick. Second Ed. Oxford University Press, 2009.

*NIH Data Management and Sharing Policy* (<https://sharing.nih.gov/data-management-and-sharing-policy/about-data-management-and-sharing-policies/data-management-and-sharing-policy-overview>), January 2023.

*Ethical Guidelines for Statistical Practice*, American Statistical Association

(<http://www.amstat.org/ASA/Your-Career/Ethical-Guidelines-for-Statistical-Practice.aspx>), April 2016.

*Introduction to RCR – 6. Data Management Practices*, Office of Research Integrity, US Department of Health and Human Services (<http://ori.hhs.gov/education/products/RCRintro/c06/0c6.html>),